Ehsan Rahimy, MD
Ophthalmology · San Carlos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Rahimy’s office at (650) 321-4121 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A114436 · Current
Licensed to practise in California · since 2010 · expires 2028-07-31 · Baylor College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Texas Q3774Physician License · since 2015 · expires 2016-05-31Canc Non-RenewalNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$2,719,035
Medicare paid this office $2,719,035 for 1,333 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, aflibercept, 1 mg | 180 | $1,217,350 | None |
| Injection, pegcetacoplan, intravitreal, 1 mg | 25 | $267,717 | None |
| Injection, aflibercept hd, 1 mg | 33 | $257,662 | None |
| Injection of drug into eye | 344 | $193,542 | $121 |
| Return visit (30+ min) | 840 | $153,582 | $112 |
See all 28 services
| Injection, aflibercept, 1 mg | 180 | $1,217,350 | None |
| Injection, pegcetacoplan, intravitreal, 1 mg | 25 | $267,717 | None |
| Injection, aflibercept hd, 1 mg | 33 | $257,662 | None |
| Injection of drug into eye | 344 | $193,542 | $121 |
| Return visit (30+ min) | 840 | $153,582 | $112 |
| Imaging of retina | 1,314 | $127,659 | $39 |
| Injection, faricimab-svoa, 0.1 mg | 24 | $104,891 | None |
| Established patient complete exam of visual system | 444 | $59,765 | $111 |
| Unclassified drugs | 20 | $45,955 | None |
| Compounded drug, not otherwise classified | 131 | $35,772 | None |
| Removal of membrane of retina | 25 | $28,774 | $1,066 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 13 | $21,038 | None |
| Destruction of eye fluid (vitreous) between lens and retina using a laser | 19 | $18,118 | $906 |
| Removal of recurring cataract in lens capsule using a laser | 35 | $14,418 | $352 |
| New patient visit (45+ min) | 83 | $11,653 | $140 |
| Short return visit (20+ min) | 113 | $10,239 | $81 |
| Extended exam of the back part of the eye with retinal drawing | 335 | $8,144 | $22 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 46 | $8,073 | $172 |
| Long return visit (40+ min) | 46 | $7,364 | $160 |
| Exchange of prosthetic lens | 11 | $6,117 | $556 |
| Photocoagulation treatment to prevent detachment of retina | 21 | $5,554 | $241 |
| Suture of iris and lens | 13 | $4,670 | $359 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 224 | $4,297 | $15 |
| New patient complete exam of visual system | 30 | $3,371 | $112 |
| Removal of recurring cataract in lens capsule by stab incision | 12 | $2,901 | $242 |
| Exam of visual field with extended testing | 28 | $1,703 | $61 |
| Measurement of corneal curvature and depth of eye | 14 | $565 | $22 |
| Photography of the retina | 13 | $481 | $34 |
Procedures Medicare counted
| Cataract surgery | 149 | More than 80% of doctors who do this |
Who their Medicare patients are
1,333 Original Medicare patients in 2024. Average age 77 · Under 65 1% · 85 and older 20% · Women 55% · Also on Medicaid 7% · Health risk score 1.11. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 64% · Diabetes 24% · Coronary heart disease 24% · Chronic kidney disease 20% · Atrial fibrillation 17% · Cancer 16% · Depression 12% · Heart failure 11% · COPD 7% · Dementia 5% · Stroke 5%.
The office billed $8,956,434, Medicare allowed $3,478,668 and paid $2,719,035; for 19,459 services of 60 kinds; $1,931,539 of it was for drugs given in the office and $787,497 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,333 | 19,459 | 77 | 1.11 | $8,956,434 | $2,719,035 |
| 2023 | 1,176 | 14,650 | 77 | 1.06 | $6,389,715 | $1,940,718 |
| 2022 | 1,053 | 10,563 | 77 | 1.09 | $5,788,145 | $1,918,857 |
| 2021 | 961 | 8,651 | 77 | 1.06 | $5,099,838 | $1,821,074 |
| 2020 | 707 | 6,207 | 77 | 1.25 | $3,579,901 | $1,304,189 |
| 2019 | 827 | 7,474 | 77 | 1.20 | $4,070,150 | $1,471,794 |
| 2018 | 661 | 6,617 | 77 | 1.18 | $3,711,287 | $1,415,825 |
| 2017 | 527 | 5,502 | 78 | 1.30 | $3,234,386 | $1,280,284 |
| 2016 | 439 | 4,426 | 78 | 1.26 | $2,964,850 | $1,133,811 |
| 2015 | 481 | 1,222 | 76 | 1.55 | $806,447 | $299,190 |
| 2014 | 399 | 730 | 71 | 1.58 | $300,721 | $98,163 |
| 2013 | 205 | 389 | 71 | 1.61 | $117,568 | $39,406 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 23 services
| Injection, aflibercept, 1 mg | 148 | $924,768 | None |
| Injection of drug into eye | 316 | $169,526 | $121 |
| Return visit (30+ min) | 730 | $132,856 | $111 |
| Imaging of retina | 1,159 | $116,371 | $39 |
| Injection, faricimab-svoa, 0.1 mg | 17 | $90,458 | None |
| Injection, pegcetacoplan, intravitreal, 1 mg | 17 | $64,995 | None |
| Established patient complete exam of visual system | 432 | $61,208 | $114 |
| Unclassified drugs | 19 | $52,224 | None |
| Compounded drug, not otherwise classified | 149 | $49,616 | None |
| Removal of membrane of retina | 20 | $24,798 | $1,078 |
| Removal of recurring cataract in lens capsule using a laser | 46 | $20,580 | $337 |
| Destruction of eye fluid (vitreous) between lens and retina using a laser | 19 | $18,517 | $882 |
| Long return visit (40+ min) | 69 | $11,713 | $163 |
| New patient visit (45+ min) | 79 | $11,239 | $142 |
| Short return visit (20+ min) | 87 | $8,882 | $83 |
| Extended exam of the back part of the eye with retinal drawing | 278 | $7,003 | $23 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 40 | $5,930 | $148 |
| Photocoagulation treatment to prevent detachment of retina | 21 | $5,687 | $237 |
| New patient complete exam of visual system | 30 | $3,658 | $122 |
| Removal of recurring cataract in lens capsule by stab incision | 13 | $3,213 | $247 |
| New patient visit (60+ min) | 14 | $2,580 | $184 |
| Exam of visual field with extended testing | 25 | $1,627 | $65 |
| Photography of the retina | 34 | $1,538 | $33 |
2022: 21 services
| Injection, aflibercept, 1 mg | 136 | $1,132,804 | None |
| Injection of drug into eye | 288 | $164,345 | $119 |
| Return visit (30+ min) | 625 | $116,010 | $110 |
| Imaging of retina | 1,043 | $107,408 | $39 |
| Established patient complete exam of visual system | 415 | $63,839 | $113 |
| Compounded drug, not otherwise classified | 143 | $46,378 | None |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 13 | $37,367 | None |
| Removal of membrane of retina | 25 | $27,553 | $1,102 |
| Removal of recurring cataract in lens capsule using a laser | 46 | $18,160 | $324 |
| New patient visit (45+ min) | 94 | $13,592 | $145 |
| Destruction of eye fluid (vitreous) between lens and retina using a laser | 13 | $12,999 | $929 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 11 | $11,853 | $1,078 |
| Short return visit (20+ min) | 117 | $9,366 | $71 |
| Photocoagulation treatment to prevent detachment of retina | 34 | $8,824 | $238 |
| Long return visit (40+ min) | 54 | $8,667 | $155 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 51 | $6,887 | $132 |
| Extended exam of the back part of the eye with retinal drawing | 173 | $4,198 | $22 |
| New patient complete exam of visual system | 19 | $1,939 | $102 |
| Photography of the retina | 42 | $1,742 | $35 |
| Exam of visual field with extended testing | 14 | $700 | $50 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 19 | $424 | $21 |
2021: 17 services
| Injection, aflibercept, 1 mg | 118 | $1,064,663 | None |
| Injection of drug into eye | 250 | $152,271 | $121 |
| Return visit (30+ min) | 631 | $107,369 | $110 |
| Imaging of retina | 932 | $100,555 | $40 |
| Compounded drug, not otherwise classified | 120 | $45,431 | None |
| Established patient complete exam of visual system | 280 | $38,803 | $122 |
| Photocoagulation treatment to prevent detachment of retina | 57 | $33,477 | $523 |
| Removal of membrane of retina | 20 | $24,659 | $1,121 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 11 | $24,342 | None |
| Removal of recurring cataract in lens capsule using a laser | 48 | $19,931 | $332 |
| Long return visit (40+ min) | 95 | $16,977 | $171 |
| New patient visit (45+ min) | 112 | $15,887 | $142 |
| Short return visit (20+ min) | 133 | $13,630 | $86 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 82 | $10,177 | $123 |
| Photography of the retina | 71 | $2,990 | $39 |
| Extended exam of the back part of the eye with retinal drawing | 106 | $2,702 | $24 |
| Exam of visual field with extended testing | 37 | $2,391 | $65 |
2020: 13 services
| Injection, aflibercept, 1 mg | 98 | $830,128 | None |
| Injection of drug into eye | 213 | $104,721 | $106 |
| Return visit (30+ min) | 633 | $94,151 | $93 |
| Imaging of retina | 678 | $68,486 | $39 |
| Compounded drug, not otherwise classified | 104 | $32,704 | None |
| Destruction of eye fluid (vitreous) between lens and retina using a laser | 11 | $10,477 | $952 |
| Photocoagulation treatment to prevent detachment of retina | 18 | $9,974 | $554 |
| New patient visit (45+ min) | 66 | $8,603 | $130 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 46 | $4,959 | $108 |
| Extended exam of the back part of the eye with retinal drawing | 107 | $2,640 | $23 |
| Telephone medical discussion with physician, 5-10 minutes | 31 | $1,288 | $42 |
| Exam of visual field with extended testing | 13 | $813 | $54 |
| Short return visit (20+ min) | 11 | $662 | $55 |
2019: 14 services
| Injection, aflibercept, 1 mg | 98 | $884,945 | None |
| Injection of drug into eye | 220 | $116,768 | $103 |
| Return visit (30+ min) | 748 | $109,735 | $93 |
| Imaging of retina | 810 | $82,591 | $39 |
| Compounded drug, not otherwise classified | 111 | $28,351 | None |
| Removal of membrane of retina | 13 | $14,111 | $1,085 |
| New patient visit (45+ min) | 84 | $11,254 | $134 |
| Photocoagulation treatment to prevent detachment of retina | 16 | $8,294 | $518 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 84 | $8,001 | $93 |
| Examination of eye by ophthalmoscope with retinal drawing | 219 | $6,690 | $27 |
| Long return visit (40+ min) | 21 | $2,797 | $133 |
| 2d ultrasound scan of eye tissue and structures | 12 | $1,251 | $60 |
| Exam of visual field with extended testing | 16 | $925 | $58 |
| Examination of eye by ophthalmoscope with retinal drawing | 26 | $653 | $25 |
2018: 15 services
| Injection, aflibercept, 1 mg | 97 | $914,622 | None |
| Injection of drug into eye | 197 | $107,162 | $103 |
| Injection, ranibizumab, 0.1 mg | 11 | $105,037 | None |
| Return visit (30+ min) | 582 | $89,736 | $92 |
| Imaging of retina | 651 | $74,464 | $39 |
| Compounded drug, not otherwise classified | 90 | $21,336 | None |
| Removal of membrane of retina | 17 | $18,056 | $1,062 |
| New patient visit (45+ min) | 76 | $10,413 | $137 |
| Photocoagulation treatment to prevent detachment of retina | 19 | $9,763 | $514 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 49 | $4,199 | $86 |
| Examination of eye by ophthalmoscope with retinal drawing | 134 | $3,579 | $26 |
| Long return visit (40+ min) | 12 | $1,772 | $136 |
| Short return visit (20+ min) | 18 | $1,310 | $66 |
| Exam of visual field with extended testing | 11 | $907 | $65 |
| Examination of eye by ophthalmoscope with retinal drawing | 26 | $650 | $24 |
2017: 11 services
| Injection, aflibercept, 1 mg | 93 | $870,578 | None |
| Injection of drug into eye | 170 | $96,550 | $103 |
| Injection, ranibizumab, 0.1 mg | 11 | $77,160 | None |
| Return visit (30+ min) | 482 | $70,794 | $91 |
| Imaging of retina | 516 | $60,446 | $39 |
| Compounded drug, not otherwise classified | 79 | $17,924 | None |
| Photocoagulation treatment to prevent detachment of retina | 12 | $6,504 | $500 |
| New patient visit (45+ min) | 40 | $5,506 | $138 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 29 | $2,575 | $86 |
| Long return visit (40+ min) | 12 | $1,624 | $135 |
| Examination of eye by ophthalmoscope with retinal drawing | 44 | $1,287 | $26 |
2016: 9 services
| Injection, aflibercept, 1 mg | 92 | $798,108 | None |
| Injection of drug into eye | 147 | $84,141 | $101 |
| Imaging of retina | 353 | $48,815 | $43 |
| Established patient complete exam of visual system | 283 | $38,822 | $117 |
| Return visit (30+ min) | 205 | $20,059 | $84 |
| Compounded drug, not otherwise classified | 67 | $12,871 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 71 | $8,627 | $111 |
| Injection, bevacizumab, 10 mg | 16 | $3,029 | None |
| New patient visit (45+ min) | 19 | $2,449 | $129 |
2015: 14 services
| Injection, aflibercept, 1 mg | 73 | $186,028 | None |
| Return visit (30+ min) | 179 | $20,161 | $104 |
| Injection of drug into eye | 111 | $17,600 | $105 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 48 | $13,338 | $267 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 72 | $11,174 | $155 |
| Imaging of retina | 161 | $10,116 | $46 |
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 26 | $6,027 | $232 |
| Removal of eye fluid (vitreous) between lens and retina | 29 | $3,372 | $116 |
| Emergency department visit with moderate level of medical decision making | 34 | $3,168 | $93 |
| Destruction of eye fluid (vitreous) between lens and retina using a laser | 15 | $1,896 | $119 |
| Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser | 13 | $1,741 | $134 |
| Removal of membrane of retina | 11 | $1,707 | $155 |
| Short return visit (20+ min) | 14 | $1,010 | $72 |
| Emergency department visit for problem that may not require health care professional | 21 | $343 | $16 |
2014: 14 services
| Removal of membrane of retina with removal of internal limiting membrane of retina | 43 | $9,300 | $211 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 38 | $8,561 | $225 |
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 30 | $7,036 | $235 |
| Established patient problem focused exam of visual system | 94 | $6,135 | $64 |
| Injection of drug into eye | 34 | $4,218 | $98 |
| Emergency department visit with moderate level of medical decision making | 41 | $3,997 | $97 |
| Imaging of retina | 84 | $3,600 | $35 |
| Removal of eye fluid (vitreous) between lens and retina | 26 | $3,415 | $131 |
| Destruction of eye fluid (vitreous) between lens and retina using a laser | 15 | $2,602 | $173 |
| New patient visit (45+ min) | 16 | $2,214 | $138 |
| Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser | 11 | $2,189 | $199 |
| Injection, bevacizumab, 10 mg | 23 | $1,608 | None |
| 2d ultrasound scan of eye tissue and structures | 19 | $1,500 | $79 |
| Emergency department visit for problem that may not require health care professional | 22 | $383 | $17 |
2013: 7 services
| Established patient problem focused exam of visual system | 96 | $7,763 | $71 |
| New patient visit (45+ min) | 19 | $2,608 | $137 |
| Imaging of retina | 60 | $2,486 | $38 |
| Injection of drug into eye | 23 | $2,259 | $87 |
| Injection, bevacizumab, 10 mg | 17 | $1,013 | None |
| Photography of the retina | 13 | $723 | $56 |
| Emergency department visit for problem that may not require health care professional | 12 | $202 | $17 |
Medicaid work
$77,578 in 2024
Medicaid paid $77,578 for 691 billed services this clinician did in 2024, up to 40 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 244 | $37,443 |
| Aflibercept injection | 45 | $31,103 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 313 | $4,997 |
| Return visit (30+ min) | 89 | $4,034 |
| 2024 | 691 | 4 | 40 | $77,578 |
| 2023 | 814 | 4 | 43 | $76,628 |
| 2022 | 479 | 3 | 31 | $34,347 |
| 2021 | 475 | 3 | 36 | $31,706 |
| 2020 | 196 | 3 | 22 | $6,438 |
| 2019 | 278 | 3 | 23 | $10,084 |
| 2018 | 149 | 2 | 20 | $8,400 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 281 | $52,890 |
| Aflibercept injection | 14 | $12,455 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 396 | $8,528 |
| Return visit (30+ min) | 123 | $2,755 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 141 | $29,300 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 269 | $3,860 |
| Return visit (30+ min) | 69 | $1,186 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 154 | $25,323 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 261 | $4,951 |
| Return visit (30+ min) | 60 | $1,432 |
2020
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 153 | $3,676 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 12 | $1,731 |
| Return visit (30+ min) | 31 | $1,031 |
2019
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 203 | $5,739 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 37 | $3,183 |
| Return visit (30+ min) | 38 | $1,162 |
2018
| Intravitreal injection of a pharmacologic agent (separate procedure) | 43 | $4,853 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 106 | $3,547 |
Drugs they prescribed that Part D paid
$23,252
Pharmacies billed $23,252 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
167 generic and 198 brand-name prescriptions · $23,252 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 150 | $7,125 | $47 |
| Fluorometholone | 16 | $1,563 | $98 |
| Difluprednate | 13 | $1,120 | $86 |
| Polymyxin B Sul-Trimethoprim | 49 | $414 | $8 |
| Dorzolamide-Timolol | 23 | $395 | $17 |
See all 7 drugs
| Prednisolone Acetate | 150 | $7,125 | $47 |
| Fluorometholone | 16 | $1,563 | $98 |
| Difluprednate | 13 | $1,120 | $86 |
| Polymyxin B Sul-Trimethoprim | 49 | $414 | $8 |
| Dorzolamide-Timolol | 23 | $395 | $17 |
| Neomycin-Polymyxin-Dexameth | 25 | $304 | $12 |
| Brimonidine | 17 | $238 | $14 |
Year by year
| 2024 | 365 | 168 | None | 54% | $23,252 |
| 2023 | 320 | 150 | 0% (0) | 61% | $27,836 |
| 2022 | 245 | 123 | 0% (0) | 65% | $16,606 |
| 2021 | 168 | 63 | 0% (0) | 58% | $11,217 |
| 2020 | 148 | 49 | None | 72% | $10,819 |
| 2019 | 144 | 59 | 0% (0) | 67% | $7,068 |
| 2018 | 110 | 43 | None | 59% | $4,598 |
| 2017 | 95 | 35 | 0% (0) | 53% | $4,391 |
| 2016 | 79 | 34 | None | 54% | $3,752 |
| 2015 | 31 | 18 | None | 39% | $1,511 |
| 2014 | 134 | 47 | 11% (15) | None | $5,529 |
| 2013 | 115 | 42 | None | 49% | $20,198 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Prednisolone Acetate | 129 | $6,790 | $53 |
| Difluprednate | 20 | $2,990 | $150 |
| Loteprednol Etabonate | 14 | $2,018 | $144 |
| Fluorometholone | 11 | $1,381 | $126 |
| Moxifloxacin | 30 | $874 | $29 |
| Latanoprost | 12 | $217 | $18 |
| Polymyxin B Sul-Trimethoprim | 18 | $174 | $10 |
| Neomycin-Polymyxin-Dexameth | 11 | $139 | $13 |
| Dorzolamide-Timolol | 12 | $133 | $11 |
2022: 6 drugs
| Prednisolone Acetate | 101 | $6,012 | $60 |
| Dorzolamide-Timolol | 18 | $623 | $35 |
| Latanoprost | 21 | $388 | $18 |
| Polymyxin B Sul-Trimethoprim | 28 | $241 | $9 |
| Neomycin-Polymyxin-Dexameth | 13 | $158 | $12 |
| Timolol Maleate | 12 | $103 | $9 |
2021: 3 drugs
| Prednisolone Acetate | 66 | $4,068 | $62 |
| Dorzolamide-Timolol | 13 | $592 | $46 |
| Polymyxin B Sul-Trimethoprim | 34 | $281 | $8 |
2020: 2 drugs
| Prednisolone Acetate | 48 | $2,843 | $59 |
| Polymyxin B Sul-Trimethoprim | 33 | $308 | $9 |
2019: 3 drugs
| Prednisolone Acetate | 58 | $3,762 | $65 |
| Polymyxin B Sul-Trimethoprim | 37 | $394 | $11 |
| Olopatadine | 12 | $350 | $29 |
2018: 2 drugs
| Prednisolone Acetate | 52 | $2,764 | $53 |
| Polymyxin B Sul-Trimethoprim | 30 | $249 | $8 |
2017: 2 drugs
| Prednisolone Acetate | 44 | $3,069 | $70 |
| Polymyxin B Sul-Trimethoprim | 29 | $262 | $9 |
2016: 2 drugs
| Prednisolone Acetate | 35 | $2,197 | $63 |
| Polymyxin B Sul-Trimethoprim | 22 | $172 | $8 |
2014: 4 drugs
| Prednisolone Acetate | 33 | $2,560 | $78 |
| Brimonidine | 16 | $802 | $50 |
| Polymyxin B Sul-Trimethoprim | 11 | $111 | $10 |
| Oxycodone-Acetaminophen | 13 | $77 | $6 |
2013: 3 drugs
| Brimonidine | 13 | $885 | $68 |
| Prednisolone Acetate | 23 | $769 | $33 |
| Dorzolamide-Timolol | 18 | $576 | $32 |
Money from drug and device companies
$244,612 in 2025
| 2025 | 13 | 162 | $226,989 | $244,612 |
| 2024 | 11 | 196 | $290,948 | $316,054 |
| 2023 | 11 | 186 | $255,846 | $282,831 |
| 2022 | 9 | 160 | $169,970 | $188,223 |
| 2021 | 6 | 187 | $186,507 | $198,593 |
| 2020 | 5 | 80 | $113,883 | $119,646 |
| 2019 | 8 | 124 | $131,086 | $148,407 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Apellis Pharmaceuticals | Syfovre | $95,367 | 53 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $88,136 | 59 payments
|
| Alcon Vision | Constellation | $14,663 | 11 payments
|
| Harrow Eye | Triesence | $10,032 | 8 payments
|
| Abbvie | Ozurdex | $9,510 | 11 payments
|
| SpringWorks Therapeutics | Gomekli | $7,985 | 1 payment
|
See all 162 published payments
| Apellis Pharmaceuticals | Paid to speak or teach · 2025-12-23 | Syfovre | $6,149 |
| Apellis Pharmaceuticals | Paid to speak or teach · 2025-12-23 | Syfovre | $7,095 |
| Regeneron Healthcare Solutions | Consulting · 2025-12-19 | Eylea Hd | $1,658 |
| Regeneron Healthcare Solutions | Consulting · 2025-12-19 | Eylea Hd | $4,973 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-12-19 | Eylea Hd | $8,840 |
| Abbvie | Paid to speak or teach · 2025-12-18 | Ozurdex | $2,550 |
| Abbvie | Paid to speak or teach · 2025-12-11 | Ozurdex | $5,950 |
| Apellis Pharmaceuticals | Travel · 2025-12-10 | Syfovre | $1,225 |
| Apellis Pharmaceuticals | Meals · 2025-12-10 | Syfovre | $125 |
| Regeneron Healthcare Solutions | Consulting · 2025-12-05 | Eylea Hd | $1,105 |
| Apellis Pharmaceuticals | Meals · 2025-12-04 | Syfovre | $123 |
| Apellis Pharmaceuticals | Travel · 2025-12-04 | Syfovre | $867 |
| Abbvie | Travel · 2025-12-03 | Ozurdex | $35 |
| Abbvie | Travel · 2025-12-02 | Ozurdex | $220 |
| Abbvie | Meals · 2025-12-02 | Ozurdex | $6 |
| Abbvie | Travel · 2025-12-02 | Ozurdex | $300 |
| Abbvie | Meals · 2025-12-02 | Ozurdex | $125 |
| Abbvie | Travel · 2025-12-02 | Ozurdex | $241 |
| Abbvie | Travel · 2025-12-02 | Ozurdex | $15 |
| Abbvie | Travel · 2025-12-02 | Ozurdex | $38 |
| Ocular Therapeutix | Consulting · 2025-12-01 | None | $1,500 |
| Regeneron Healthcare Solutions | Consulting · 2025-11-21 | Eylea | $553 |
| Regeneron Healthcare Solutions | Consulting · 2025-11-21 | Eylea | $3,315 |
| Regeneron Healthcare Solutions | Consulting · 2025-11-21 | Eylea | $4,420 |
| Alcon Vision | Meals · 2025-11-20 | Unity | $22 |
| Alcon Vision | Meals · 2025-11-20 | Constellation | $7 |
| Alcon Vision | Meals · 2025-11-20 | Unity | $17 |
| Alcon Vision | Consulting · 2025-11-20 | Constellation | $13,500 |
| Alcon Vision | Travel · 2025-11-20 | Unity | $48 |
| Alcon Vision | Travel · 2025-11-20 | Unity | $37 |
| Alcon Vision | Travel · 2025-11-20 | Unity | $183 |
| Regeneron Healthcare Solutions | Travel · 2025-11-18 | Eylea Hd | $407 |
| Alcon Vision | Meals · 2025-11-14 | Ngenuity | $151 |
| Alcon Vision | Travel · 2025-11-14 | Unity | $168 |
| Alcon Vision | Travel · 2025-11-14 | Finesse Sharkskin | $225 |
| Alcon Vision | Travel · 2025-11-14 | Constellation | $304 |
| Apellis Pharmaceuticals | Consulting · 2025-11-14 | Syfovre | $36 |
| Apellis Pharmaceuticals | Consulting · 2025-11-14 | Syfovre | $6,149 |
| Regeneron Healthcare Solutions | Travel · 2025-11-09 | Eylea Hd | $156 |
| Regeneron Healthcare Solutions | Meals · 2025-11-08 | Eylea Hd | $135 |
| Alcon Research | Consulting · 2025-11-06 | Ngenuity | $1,000 |
| Alcon Research | Consulting · 2025-11-06 | None | $500 |
| Harrow Eye | Meals · 2025-10-30 | Triesence | $147 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-10-28 | Eylea Hd | $2,619 |
| Regeneron Healthcare Solutions | Travel · 2025-10-24 | Eylea Hd | $259 |
| Apellis Pharmaceuticals | Consulting · 2025-10-24 | Syfovre | $1,892 |
| Alcon Research | Consulting · 2025-10-23 | None | $1,000 |
| Regeneron Healthcare Solutions | Travel · 2025-10-21 | Eylea Hd | $47 |
| Apellis Pharmaceuticals | Meals · 2025-10-17 | None | $121 |
| Apellis Pharmaceuticals | Consulting · 2025-10-10 | Syfovre | $3,784 |
| Apellis Pharmaceuticals | Consulting · 2025-10-10 | Syfovre | $3,784 |
| Regeneron Healthcare Solutions | Meals · 2025-10-03 | Eylea | $103 |
| Apellis Pharmaceuticals | Paid to speak or teach · 2025-10-01 | Syfovre | $1,500 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-09-30 | Eylea Hd | $6,630 |
| Regeneron Healthcare Solutions | Meals · 2025-09-25 | Eylea Hd | $105 |
| Apellis Pharmaceuticals | Consulting · 2025-09-19 | Syfovre | $4,257 |
| Apellis Pharmaceuticals | Travel · 2025-09-19 | Syfovre | $206 |
| Alcon Research | Consulting · 2025-09-18 | None | $500 |
| Apellis Pharmaceuticals | Meals · 2025-09-12 | None | $55 |
| Regeneron Pharmaceuticals | Consulting · 2025-09-05 | Eylea Hd | $3,315 |
| Harrow Eye | Consulting · 2025-09-04 | Triesence | $2,800 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-08-19 | Eylea Hd | $2,763 |
| Regeneron Pharmaceuticals | Meals · 2025-08-15 | Eylea Hd | $122 |
| Regeneron Pharmaceuticals | Meals · 2025-08-15 | Eylea Hd | $18 |
| Regeneron Pharmaceuticals | Meals · 2025-08-15 | Eylea Hd | $42 |
| Harrow Eye | Consulting · 2025-08-10 | Iheezo | $700 |
| Regeneron Pharmaceuticals | Meals · 2025-08-01 | Eylea Hd | $33 |
| Abbvie | Meals · 2025-07-31 | Ozurdex | $31 |
| Neurotech Pharmaceuticals | Consulting · 2025-07-31 | None | $3,633 |
| Apellis Pharmaceuticals | Meals · 2025-07-29 | None | $49 |
| Regeneron Healthcare Solutions | Consulting · 2025-07-25 | Eylea Hd | $1,105 |
| Regeneron Healthcare Solutions | Consulting · 2025-07-25 | Eylea Hd | $1,105 |
| SpringWorks Therapeutics | Consulting · 2025-07-17 | Gomekli | $7,985 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-07-01 | Eylea Hd | $2,763 |
| Regeneron Healthcare Solutions | Travel · 2025-06-24 | Eylea Hd | $38 |
| Regeneron Healthcare Solutions | Meals · 2025-06-24 | Eylea Hd | $53 |
| Regeneron Healthcare Solutions | Travel · 2025-06-24 | Eylea Hd | $8 |
| Regeneron Healthcare Solutions | Travel · 2025-06-24 | Eylea Hd | $31 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-06-20 | Eylea Hd | $1,989 |
| Apellis Pharmaceuticals | Meals · 2025-06-19 | Syfovre | $120 |
| Apellis Pharmaceuticals | Travel · 2025-06-19 | Syfovre | $1,225 |
| Apellis Pharmaceuticals | Paid to speak or teach · 2025-06-19 | Syfovre | $6,149 |
| Astellas Pharma Global Development | Meals · 2025-06-17 | Izervay | $160 |
| Regeneron Healthcare Solutions | Consulting · 2025-06-13 | Eylea Hd | $3,315 |
| Regeneron Healthcare Solutions | Consulting · 2025-06-13 | Eylea Hd | $3,868 |
| Apellis Pharmaceuticals | Consulting · 2025-06-06 | Syfovre | $1,892 |
| Apellis Pharmaceuticals | Consulting · 2025-06-06 | Syfovre | $4,730 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-06-04 | Eylea Hd | $8,840 |
| Regeneron Healthcare Solutions | Meals · 2025-05-30 | Eylea Hd | $135 |
| Regeneron Healthcare Solutions | Travel · 2025-05-30 | Eylea Hd | $1,035 |
| Regeneron Healthcare Solutions | Meals · 2025-05-29 | Eylea Hd | $92 |
| Harrow Eye | Consulting · 2025-05-28 | Triesence | $700 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-05-23 | Eylea Hd | $2,763 |
| Regeneron Healthcare Solutions | Meals · 2025-05-22 | Eylea Hd | $25 |
| Apellis Pharmaceuticals | Travel · 2025-05-14 | Syfovre | $1,133 |
| Apellis Pharmaceuticals | Meals · 2025-05-14 | Syfovre | $125 |
| Apellis Pharmaceuticals | Paid to speak or teach · 2025-05-14 | Syfovre | $7,095 |
| Harrow Eye | Meals · 2025-05-10 | Vevye | $60 |
| Harrow Eye | Consulting · 2025-05-09 | Triesence | $2,800 |
| Apellis Pharmaceuticals | Meals · 2025-05-08 | None | $148 |
| Regeneron Healthcare Solutions | Travel · 2025-05-07 | Eylea Hd | $100 |
| Regeneron Healthcare Solutions | Travel · 2025-05-07 | Eylea Hd | $88 |
| Regeneron Healthcare Solutions | Meals · 2025-05-06 | Eylea Hd | $116 |
| Apellis Pharmaceuticals | Meals · 2025-04-24 | Syfovre | $125 |
| Apellis Pharmaceuticals | Travel · 2025-04-24 | Syfovre | $16 |
| Apellis Pharmaceuticals | Travel · 2025-04-24 | Syfovre | $165 |
| Apellis Pharmaceuticals | Travel · 2025-04-24 | Syfovre | $202 |
| Apellis Pharmaceuticals | Travel · 2025-04-24 | Syfovre | $517 |
| Apellis Pharmaceuticals | Meals · 2025-04-24 | Syfovre | $6 |
| Apellis Pharmaceuticals | Paid to speak or teach · 2025-04-24 | Syfovre | $8,041 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-04-11 | Eylea Hd | $2,210 |
| Apellis Pharmaceuticals | Consulting · 2025-04-11 | Syfovre | $10,406 |
| Regeneron Healthcare Solutions | Consulting · 2025-04-04 | Eylea Hd | $1,105 |
| Regeneron Healthcare Solutions | Consulting · 2025-04-04 | Eylea Hd | $1,105 |
| Regeneron Healthcare Solutions | Consulting · 2025-04-04 | Eylea Hd | $1,658 |
| Harrow Eye | Meals · 2025-03-28 | Iheezo | $24 |
| Apellis Pharmaceuticals | Paid to speak or teach · 2025-03-25 | Syfovre | $1,500 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-03-21 | Eylea Hd | $6,078 |
| Apellis Pharmaceuticals | Paid to speak or teach · 2025-03-20 | Syfovre | $4,730 |
| Regeneron Healthcare Solutions | Travel · 2025-03-18 | Eylea Hd | $400 |
| Regeneron Healthcare Solutions | Meals · 2025-03-15 | Eylea Hd | $32 |
| Regeneron Healthcare Solutions | Consulting · 2025-03-07 | Eylea Hd | $1,105 |
| Regeneron Healthcare Solutions | Consulting · 2025-03-07 | Eylea Hd | $553 |
| Apellis Pharmaceuticals | Meals · 2025-03-04 | Syfovre | $60 |
| Apellis Pharmaceuticals | Meals · 2025-03-04 | Syfovre | $10 |
| Apellis Pharmaceuticals | Travel · 2025-03-04 | Syfovre | $396 |
| Apellis Pharmaceuticals | Meals · 2025-03-04 | Syfovre | $20 |
| Apellis Pharmaceuticals | Meals · 2025-03-04 | Syfovre | $119 |
| Apellis Pharmaceuticals | Travel · 2025-03-04 | Syfovre | $593 |
| Apellis Pharmaceuticals | Travel · 2025-03-04 | Syfovre | $166 |
| Apellis Pharmaceuticals | Travel · 2025-03-04 | Syfovre | $148 |
| Apellis Pharmaceuticals | Travel · 2025-03-04 | Syfovre | $584 |
| Apellis Pharmaceuticals | Travel · 2025-03-04 | Syfovre | $741 |
| Apellis Pharmaceuticals | Travel · 2025-03-04 | Syfovre | $833 |
| Apellis Pharmaceuticals | Travel · 2025-03-04 | Syfovre | $125 |
| Apellis Pharmaceuticals | Meals · 2025-03-03 | Syfovre | $118 |
| Apellis Pharmaceuticals | Consulting · 2025-02-21 | Syfovre | $946 |
| Apellis Pharmaceuticals | Travel · 2025-02-12 | Syfovre | $5 |
| Dutch Ophthalmic USA | Meals · 2025-02-10 | Eva, Combined Machine | $166 |
| Regeneron Healthcare Solutions | Meals · 2025-02-04 | Eylea Hd | $41 |
| Regeneron Healthcare Solutions | Travel · 2025-01-24 | Eylea Hd | $51 |
| Regeneron Healthcare Solutions | Travel · 2025-01-24 | Eylea Hd | $29 |
| Regeneron Healthcare Solutions | Meals · 2025-01-24 | Eylea Hd | $7 |
| Regeneron Healthcare Solutions | Meals · 2025-01-24 | Eylea Hd | $6 |
| Apellis Pharmaceuticals | Consulting · 2025-01-21 | Syfovre | $4,730 |
| Harrow Eye | Consulting · 2025-01-20 | Iheezo | $2,800 |
| Regeneron Healthcare Solutions | Consulting · 2025-01-17 | Eylea Hd | $7,735 |
| Genentech USA | Meals · 2025-01-16 | Vabysmo | $11 |
| Genentech USA | Meals · 2025-01-16 | Vabysmo | $25 |
| Genentech USA | Travel · 2025-01-16 | Vabysmo | $21 |
| Genentech USA | Travel · 2025-01-16 | Vabysmo | $38 |
| Regeneron Pharmaceuticals | Meals · 2025-01-13 | Eylea Hd | $118 |
| Genentech USA | Paid to speak or teach · 2025-01-09 | Vabysmo | $6,720 |
| Regeneron Healthcare Solutions | Travel · 2025-01-09 | Eylea Hd | $38 |
| Regeneron Healthcare Solutions | Meals · 2025-01-09 | Eylea Hd | $43 |
| Regeneron Healthcare Solutions | Travel · 2025-01-09 | Eylea Hd | $23 |
| Regeneron Healthcare Solutions | Travel · 2025-01-08 | Eylea Hd | $49 |
| Regeneron Healthcare Solutions | Travel · 2025-01-08 | Eylea Hd | $100 |
| Regeneron Healthcare Solutions | Meals · 2025-01-08 | Eylea Hd | $8 |
| Regeneron Healthcare Solutions | Meals · 2025-01-08 | Eylea Hd | $32 |
| Regeneron Healthcare Solutions | Travel · 2025-01-08 | Eylea Hd | $170 |
| Apellis Pharmaceuticals | Meals · 2025-01-08 | Syfovre | $30 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $316,054
| Apellis Pharmaceuticals | Syfovre | $121,682 | 64 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $110,721 | 63 payments
|
| Abbvie | None | $24,135 | 24 payments
|
| Alcon Vision | Constellation | $18,948 | 11 payments
|
| Regeneron Pharmaceuticals | Eylea Hd | $13,813 | 5 payments
|
| Genentech USA | Susvimo | $7,964 | 10 payments
|
| EyePoint Pharmaceuticals US | Eyp-1901 | $7,088 | 8 payments
|
| Carl Zeiss Meditec USA | Cirrus Hd-Oct | $5,472 | 5 payments
|
| F. Hoffmann-La Roche AG | None | $3,780 | 1 payment
|
| Astellas Pharma US | Izervay | $2,350 | 4 payments
|
| Tarsus Pharmaceuticals | Xdemvy | $102 | 1 payment
|
2023: $282,831
| Regeneron Healthcare Solutions | Eylea Hd | $143,554 | 91 payments
|
| Apellis Pharmaceuticals | Syfovre | $59,100 | 40 payments
|
| Genentech USA | Vabysmo | $44,184 | 27 payments
|
| Abbvie | Ozurdex | $16,354 | 13 payments
|
| Genentech | Vabysmo | $10,316 | 5 payments
|
| Regeneron Pharmaceuticals | Eylea Hd | $4,792 | 3 payments
|
| Astellas Pharma US | Izervay | $2,899 | 3 payments
|
| Alcon Research | None | $700 | 1 payment
|
| Carl Zeiss Meditec | Forum | $680 | 1 payment
|
| Biogen | None | $128 | 1 payment
|
| Alcon Vision | Ngenuity | $123 | 1 payment
|
2022: $188,223
| Regeneron Healthcare Solutions | Eylea | $92,363 | 75 payments
|
| Apellis Pharmaceuticals | None | $36,248 | 28 payments
|
| Abbvie | Ozurdex | $26,518 | 37 payments
|
| Genentech USA | Vabysmo | $17,889 | 12 payments
|
| Regeneron Pharmaceuticals | Eylea | $11,132 | 3 payments
|
| Carl Zeiss Meditec | Artevo 800 | $2,040 | 1 payment
|
| Bausch & Lomb Americas | Visudyne | $1,797 | 2 payments
|
| Genentech | Vabysmo | $120 | 1 payment
|
| Allergan | Ozurdex | $117 | 1 payment
|
2021: $198,593
| Regeneron Healthcare Solutions | Eylea | $140,590 | 107 payments
|
| Allergan | Ozurdex | $48,315 | 70 payments
|
| Apellis Pharmaceuticals | None | $3,640 | 1 payment
|
| Carl Zeiss Meditec | Cirrus 5000 | $3,240 | 3 payments
|
| Genentech USA | Lucentis | $2,687 | 4 payments
|
| Alcon Vision | Ngenuity | $121 | 2 payments
|
2020: $119,646
| Regeneron Healthcare Solutions | Eylea | $105,967 | 69 payments
|
| Allergan | Ozurdex | $7,228 | 6 payments
|
| Genentech | Lucentis | $2,420 | 1 payment
|
| Carl Zeiss Meditec | Artevo 800 | $2,412 | 3 payments
|
| EyePoint Pharmaceuticals US | Yutiq | $1,620 | 1 payment
|
2019: $148,407
| Regeneron Healthcare Solutions | Eylea | $137,352 | 105 payments
|
| Allergan | Ozurdex | $9,506 | 11 payments
|
| Alimera Sciences | Iluvien | $1,085 | 2 payments
|
| Dutch Ophthalmic USA | Eva Ophthalmic Surgical System | $167 | 1 payment
|
| Genentech USA | Lucentis | $122 | 2 payments
|
| Optos | P200dtx | $72 | 1 payment
|
| Carl Zeiss Meditec | None | $70 | 1 payment
|
| Novartis Pharmaceuticals | None | $33 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| F. Hoffmann-La Roche AG · Va2 Phiii Yosemite · 2024 | This clinician | $6,174 |
| Regeneron Pharmaceuticals, Inc. · Health Economics Outcome Research Related To Opthalmology · 2024 | This clinician | $5,325 |
| Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2020 | This clinician | $3,647 |
| F. Hoffmann-La Roche AG · Va2 Phiii Yosemite · 2025 | This clinician | $1,879 |
| Regeneron Pharmaceuticals, Inc. · A Double- Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of Vegf Trap-Eye in Patients With Diabetic Macular Edema · 2020 | This clinician | $1,664 |
| F. Hoffmann-La Roche AG · Faricimab Causes Rapid and Sustained Intraocular Suppression of Ang-2 and Vegf-A for Up To 16 Weeks in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema · 2024 | This clinician | $1,654 |
| Regeneron Pharmaceuticals, Inc. · Health Economics Outcome Research Related To Opthalmology · 2022 | This clinician | $1,116 |
| Regeneron Pharmaceuticals, Inc. · Health Economics and Outcomes Research (Heor) · 2020 | This clinician | $616 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration · 2022 | This clinician | $365 |
Professional record
- NPI
- 1255573606
- Licence
- CA A114436, TX Q3774California A114436: Current · expires 2028-07-31Texas Q3774: Canc Non-Renewal
- Trained
- Baylor College of Medicine, 2009
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0107X (207WX0107X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2009-04-01
- NPI last updated
- 2024-03-21
- NPI record certified
- 2024-03-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 795 El Camino Real, Palo Alto, CA, 94301 · 301 Industrial Rd, San Carlos, CA, 94070